Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) dropped 4.5% on Wednesday . The stock traded as low as $25.95 and last traded at $25.99, with a volume of 788,901 shares traded. The stock had previously closed at $27.21.

SRPT has been the topic of several recent research reports. Ladenburg Thalmann lowered Sarepta Therapeutics from a “market perform” rating to an “underperform” rating and decreased their price objective for the stock from $13.00 to $5.00 in a report on Thursday, May 5th. Jefferies Group reissued a “sell” rating and set a $7.00 price objective on shares of Sarepta Therapeutics in a report on Friday, May 6th. Robert W. Baird reissued a “buy” rating on shares of Sarepta Therapeutics in a report on Sunday, May 8th. Vetr raised Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $17.28 price objective on the stock in a report on Thursday, May 12th. Finally, Wedbush reissued a “neutral” rating and set a $14.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, May 25th. Five equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $23.60.

The company’s market capitalization is $1.29 billion. The company’s 50 day moving average price is $24.98 and its 200-day moving average price is $19.69.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same period last year, the business earned ($0.87) earnings per share. Analysts expect that Sarepta Therapeutics Inc. will post ($5.16) EPS for the current fiscal year.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.